Thrombin-Induced Platelet Activation Is Inhibited by High- and Low-Molecular-Weight Heparin

E. De Candia, MD; R. De Cristofaro, MD; R. Landolfi, MD

Background—Thrombin binds to platelet glycoprotein Ib (Gp Ib), and this interaction contributes to platelet activation. Thrombin ligation to Gp Ib was recently shown to be inhibited by heparin, thus raising the hypothesis, investigated in this article, that heparin might inhibit thrombin-induced platelet activation.

Methods and Results—Aggregation of gel-filtered platelets by 1 nmol/L thrombin was reduced by both high-molecular-weight (MW) (14 500-Da) and low-MW (4500-Da) heparin, with IC₅₀ values of 1.65±0.26 and 5.13±0.8 μmol/L, respectively. Homogeneous-MW fractions (16 000- to 13 000-Da range) were used to evaluate the heparin effect on intracytoplasmic calcium release by thrombin. Calcium mobilization by 1 nmol/L thrombin was reduced as a function of heparin concentration, and the inhibitory effect was correlated to the MW of heparin fractions (IC₅₀ values were 1.9±0.39, 6.07±0.83, and 14.8±0.43 μmol/L for 16 000-, 9000-, and 3000-Da heparin, respectively). Platelet aggregation and calcium mobilization by ADP and by the thrombin receptor–activating peptide were not affected by heparin. The activation of Gp Ib–depleted platelets by α-thrombin was not inhibited by heparin. Moreover, platelet stimulation by heparin binding site phosphopyridoxylated thrombin, which has a severe impairment of Gp Ib ligation, was not affected by heparin. Finally, heparin did not interfere with the hydrolysis by thrombin of the protease-activated receptor 1.

Conclusions—These results demonstrated that heparin, by inhibiting the thrombin–Gp Ib interaction, is able to interfere with thrombin-induced platelet activation. The extent of the inhibitory effect is directly related to the MW of heparin fractions. (Circulation. 1999;99:3308-3314.)

Key Words: platelets ■ receptors ■ glycoproteins ■ heparin

Thrombin-induced platelet activation is mediated primarily by the hydrolysis of a G-protein–coupled receptor on the membrane, referred to as protease-activated receptor 1 (PAR-1). Another receptor (PAR-4), recently described in mouse and human platelets, has a low sensitivity to thrombin and a more uncertain role. Thrombin also binds to the platelet glycoprotein (GP) Ib/X/V complex, and the binding site has been localized to the 45 000 Da N-terminal region of Gp Ib α-chain, which also bears a binding site for von Willebrand factor (vWF). Thrombin interaction with Gp Ib contributes to full platelet activation. In fact, Bernard-Soulier platelets, which lack Gp Ib, show a reduced response to thrombin. In addition, the anti-Gp Ib monoclonal antibodies directed against the thrombin-binding domain inhibit in vitro platelet activation by thrombin.

It was recently demonstrated that thrombin binds to Gp Ib through an anion-binding exosite referred to as a heparin-binding site (HBS). This is an Arg/Lys-rich surface patch located near the C-terminal helix of the thrombin B-chain. The binding of thrombin to purified glycopcalcin, the soluble extracytoplasmic portion of Gp Ib, was inhibited by heparin as well as by chemically induced modification of the thrombin HBS. Moreover, when a solid-phase assay was used, thrombin binding to immobilized glycopcalcin was displaced by heparin and by the prothrombin fragment 2, which also binds to the thrombin HBS. Furthermore, glycopcalcin binding to thrombin was demonstrated to compete with heparin for thrombin inactivation by the antithrombin III (ATIII)–heparin complex.

In the present study, we investigated the hypothesis that heparin, by inhibiting thrombin–Gp Ib interaction, might affect platelet activation by thrombin.

Methods

Reagents

High-molecular-weight (HMW) (MW ~14 500) porcine heparin from intestinal mucosa was purchased from Calbiochem. Low-molecular-weight (LMW) (MW ~4500) heparin, CY 216, was provided by Sanofi. Heparin fractions with homogeneous MWs (16 000, 9000, and 3000 Da) were from Enzyme Research. Purified bovine factor Xa, fura 2-AM, and the thrombin receptor–activating peptide SFLLRNPNDKYEPF (TRAP) were from Sigma. The protease synthetic substrate N-α-Cholyl-d-Arg-Gly-Arg-p-nitroanilide was from Chromogenix. Human ATIII was obtained from Enzyme Research. d-Phenylalanyl-l-prolyl-l-arginine chloromethyl ketone (PPACK) was from Calbiochem. The CD42b...
monoclonal antibody was kindly provided by Instrumentation Laboratory.

Mocarhagin was kindly provided by Dr Robert K. Andrews (Baker Medical Research Institute, Prahran, Australia).

Human α-thrombin was purified and characterized as previously detailed.10

HBS-phosphoryridoxylated (PLP)-thrombin was prepared and evaluated as to its clotting activity and residual sensitivity to heparin by previously described methods.8,11,12

D-Phenylalanyl-l-prolyl-l-arginine chloromethyl ketone–thrombin (PPACK-thrombin) was prepared as previously described.13

PPACK-thrombin preparation had no catalytic activity.

Aggregometric Studies

Platelet-rich plasma (PRP) obtained from healthy donors was gel-filtered on Sepharose 2B columns and eluted in buffer: 20 mmol/L HEPES, 135 mmol/L NaCl, 5 mmol/L KCl, 5.5 mmol/L glucose, and 0.2% BSA, pH 7.4. The platelet count was adjusted to 2×10^7/µL.

Gel-filtered platelets incubated with HMW (MW ~14 500) heparin concentrations ranging from 0.29 to 76 µmol/L and LMW (MW ~4500) heparin concentrations ranging from 0.156 to 87 µmol/L were stimulated by 1 nmol/L thrombin at 37°C. In other experiments, gel-filtered platelets were incubated with 20 µmol/L HMW heparin and stimulated by 10 µmol/L TRAP. Aggregometric responses were evaluated by measuring the initial slope of the aggregometric curve and expressed as percentage of residual effect with respect to control, ie, platelets without heparin.

For ADP-induced platelet aggregation, PRP was adjusted to a platelet count of 2×10^7/µL with autologous platelet-poor plasma. PRP was incubated with 150 µmol/L HMW heparin and aggregated by 4 µmol/L ADP (final concentration).

Measurements of Intraplatelet Ca^{2+} Mobilization

Measurements of intraplatelet Ca^{2+} concentration were performed by use of the fluorescent dye for Ca^{2+} fura 2–acetoxymethyl ester (fura 2-AM) as previously described.14 The influx of external calcium was avoided by adding 1 mmol/L EDTA to platelet suspensions. Fura 2–loaded platelets were incubated with HBS-phosphopyridoxylated (PLP)-thrombin (PPACK-thrombin) was prepared as previously described.13

PPACK-thrombin preparation had no catalytic activity.

Effect of Heparin on Platelet Aggregation

Increasing concentrations of HMW heparin caused a progressive inhibition of aggregation induced by 1 nmol/L thrombin, whereas aggregation by ADP was not affected by 150 µmol/L HMW heparin (Figure 1). In addition, the aggregation of gel-filtered platelets by TRAP was not affected by 20 µmol/L HMW heparin (data not shown).

LMW heparin also inhibited, although to a lesser degree, the aggregation of gel-filtered platelets by thrombin. In Figure 2, the inhibitory effect of different concentrations of both HMW and LMW heparins is shown. As explained in the legend of Figure 2, the fit of the experimental data suggested that the inhibitory effect of both heparins reached an asymptotic value at [heparin] = ∞. These findings indicate that the thrombin-induced platelet aggregation was markedly inhibited but not abolished by heparin.

It was excluded that the heparin effect could be attributed to the presence of residual ATIII in the platelet suspension (see Methods).

Intraplatelet Calcium Mobilization by α-Thrombin and HBS-PLP-Thrombin

The effect of HMW (16 000-Da), intermediate-MW (9000-Da), and LMW (3000-Da) heparins on calcium mobilization was evaluated by measuring the LT for calcium increase induced by α-thrombin. As shown in Figure 3, heparin caused a dose-dependent inhibition of calcium mobilization induced by 1 mmol/L α-thrombin. Figure 4 reports the effects of heparins with different MWs. The extent of the inhibitory effect was directly related to the MW of heparin fractions. In fact, there was a linear correlation between IC_{50} values and the MWs of heparins (Figure 5).
The minor differences in IC_{50} values obtained with aggregometric and calcium experiments were attributed to the different experimental conditions. As already shown for aggregometric experiments, the effect of heparin was specific for thrombin-induced Ca^{2+} changes, because ADP-induced Ca^{2+} changes were not affected by 40 μmol/L heparin (data not shown).

To confirm that the observed effect could be attributed to inhibition of thrombin HBS binding to Gp Ib, we performed further experiments with HBS-PLP-thrombin. Control assays demonstrated that HBS-PLP-thrombin sensitivity to heparin was almost abolished. We have previously shown that the binding of HBS-PLP-thrombin to purified glycocalcin in solution is markedly reduced with respect to the wild-type enzyme (≈10-fold reduction). As shown in Figure 6, the HBS-PLP-thrombin, compared with native α-thrombin, induced a delayed calcium mobilization. Furthermore, platelet response to the HBS-modified thrombin was not significantly modified by increasing concentrations of HMW heparin (Figure 7).

**Calcium Mobilization in Gp Ib–Depleted Platelets: Effect of Heparin**

To confirm that a perturbation of thrombin–Gp Ib interaction was the mechanism underlying the inhibition by heparin, we also tested the heparin effect on platelets, which had been

![Figure 1. Aggregometric curves of platelets stimulated by α-thrombin and ADP in absence and presence of heparin. Washed platelets were stimulated by 1 nmol/L α-thrombin in presence of increasing (from left to right, 0, 2.3, 9.4, 18, and 37 μmol/L) concentrations of HMW (14 500-Da) heparin. Only 4 of 8 different curves are reported. Bottom, curves obtained by stimulating PRP with 4 μmol/L ADP in absence (left) and presence (right) of 150 μmol/L HMW heparin.](image-url)
depleted of Gp Ib by mocarhagin. Figure 8 shows that mocarhagin-treated platelets mimic a Bernard-Soulier–like response. Gp Ib–depleted and intact platelets from the same donor were stimulated by \( \alpha \)-thrombin in the presence of increasing concentrations of HMW and LMW heparin. Mocarhagin-treated platelets were markedly less sensitive to heparin than were intact platelets (Figure 9). This last finding indicates that the inhibitory effect of heparin on thrombin-induced platelet activation is directly related to an inhibition of thrombin binding to Gp Ib.

**Calcium Mobilization by PPACK-Thrombin**

This study was carried out to evaluate whether the binding of an active-site–blocked thrombin to the platelet membrane might induce a calcium mobilization. Preliminary experiments carried out by cytofluorimetric assays showed that PPACK-thrombin was able to displace a specific anti–Gp Ib monoclonal antibody from its binding to the platelet membrane (data not shown). Thus, PPACK-thrombin retains its ability to bind to Gp Ib.

We measured the calcium mobilization induced by 150 nmol/L PPACK-thrombin, a concentration able to saturate the Gp Ib binding site. In our experimental conditions, ie, in the presence of external EDTA and without stirring, no cytoplasmic Ca\(^{2+} \) increase was observed (Figure 10). This result indicates that \( \alpha \)-thrombin binding to Gp Ib does not itself induce a calcium response; therefore, an active enzyme is required to activate platelets via Gp Ib.
Effect of Heparin on the Hydrolysis of PAR-1 Peptide 38-60

The possible heparin effect on thrombin interaction with PAR-1 was investigated by evaluating the hydrolysis by \( \alpha \)-thrombin of the peptide PAR-1 38-60 in the presence of HMW heparin. PAR-1 38-60 peptide contains both the cleavage site and the hirudin-like domain of PAR-1. As shown in Figure 11, the kinetics of peptide hydrolysis was not affected by HMW heparin. This result is in agreement with previous demonstrations that modifications at the thrombin HBS8 and glyocalcisin binding to thrombin \( \alpha \) did not change the \( k_{\text{cat}} \) and \( K_m \) values pertaining to PAR-1–derived peptide hydrolysis.

Figures:

- **Figure 5.** IC\(_{50}\) values as a function of MW of heparin fractions. IC\(_{50}\) values obtained from calcium experiments are reported as a function of heparin MW. Continuous line, drawn according to a linear regression, shows that IC\(_{50}\) values are linearly correlated to MW of heparin fractions.

- **Figure 6.** Calcium mobilization by HBS-PLP-thrombin and \( \alpha \)-thrombin. Plot of LT values pertaining to intraplatelet calcium increase as a function of wild-type \( \alpha \)-thrombin (●) and HBS-PLP-thrombin (●) concentrations. At each thrombin concentration, calcium mobilization by HBS-PLP-thrombin was markedly delayed compared with native \( \alpha \)-thrombin.

- **Figure 7.** Effect of heparin on HBS-PLP-thrombin–induced platelet activation. Values of LT\(_{\text{obs}}/LT_0\) ratio for HBS-PLP-thrombin (●)–induced calcium mobilization are reported as a function of HMW (14,500-Da) heparin concentration and compared with that obtained with \( \alpha \)-thrombin (○). Both thrombins were used at concentration of 2.5 nmol/L. Continuous lines were drawn according to an inhibition equation that provided IC\(_{50}\) values of 76 ± 10 and 6 ± 0.9 \( \mu \)mol/L for HBS-PLP-thrombin and \( \alpha \)-thrombin, respectively.

- **Figure 8.** Effect of platelet mocraginah treatment on calcium response by \( \alpha \)-thrombin. Mocraginah-treated platelets (right) show a decreased response to 1 nmol/L \( \alpha \)-thrombin compared with intact platelets (left). LT for calcium increase is prolonged, as in Bernard-Soulier platelets.

Discussion

The present study shows that heparin, in the micromolar range, is able to inhibit thrombin-induced platelet activation.

The inhibitory effect of heparin could be demonstrated both on platelet aggregation, which is the final effect of thrombin activation, and on cytosolic calcium mobilization. Because the latter is one of the most rapid biochemical responses to thrombin, heparin was shown to inhibit the very early phases of platelet activation by thrombin. The extent of the inhibitory effect was related to the MW of heparin fractions, being more evident for HMW than for LMW fractions.

The inhibitory effect of heparin was specific for thrombin-induced platelet activation and could be attributed to the inhibition of thrombin binding to Gp Ib. Several findings support this hypothesis. Thrombin modified at the HBS, ie, HBS-PLP-thrombin, which has a 10-fold affinity reduction for Gp Ib with respect to native \( \alpha \)-thrombin,⁸ had a markedly decreased activatory effect. This effect, in addition, could not
be further inhibited by heparin. This finding and the evidence that platelets depleted of Gp Ib by mocarhagin treatment lose their sensitivity to heparin allowed us to conclude that the mechanism of heparin inhibition is Gp Ib–dependent. Finally, we ruled out a possible perturbation of the interaction of the enzyme with PAR-1, because the hydrolysis of PAR-138-60 was not affected by heparin. The linear relationship between the MW of heparin and the IC50 values constitutes an indirect demonstration that the heparin effect is mediated by its binding to thrombin. This interaction is driven mostly by electrostatic bonds,17,18 and as a consequence, the inhibitory effect of heparin depends on the number of electrostatic charges per mole of heparin chain. Altogether, the above findings rule out the possibility that additional and/or non-specific mechanisms might play a role in the heparin effect.

The present study, in addition to providing novel findings about the effects of heparin on platelet function and confirming structural evidence regarding the thrombin HBS interaction with platelet Gp Ib, points out the role of Gp Ib in platelet activation. The possibility of a direct signal transduction on Gp Ib binding by an agonist was raised by the evidence that vWF binding to Gp Ib is able to cause intraplatelet calcium elevation.19 This finding has been attributed to the influx of extracellular calcium due to the activation of some membrane calcium channels by vWF ligation to Gp Ib. This mechanism was not possible in our experimental conditions because all the calcium experiments shown in the present study were carried out in the absence of external calcium. However, we investigated the possibility of a direct signal transduction via Gp Ib by studying platelet activation by PPACK-thrombin. This catalytically inactive thrombin form binds to Gp Ib as the native enzyme but is unable to cleave PAR-1. PPACK-thrombin concentrations that are able to saturate the binding to Gp Ib (150 nmol/L) caused no calcium increase. This indicates that the simple thrombin binding to Gp Ib is unable to induce platelet activation, although it contributes to thrombin-induced activation by a different mechanism, whose evaluation is not in the realm of this study.

Because of its mechanism of action, heparin could not completely suppress the platelet activation by thrombin. Although the interaction of thrombin with Gp Ib is impaired in the presence of heparin, the enzyme can equally cleave PAR-1 on the platelet membrane and evoke a platelet response. Also, Bernard-Soulier platelets5 or platelets in which Gp Ib is enzymatically cleaved by Serratia marcescens protease20 or mocarhagin15 have a marked delay but not a complete suppression of platelet response by thrombin. Moreover, in agreement with the described heparin mechanism of action, Gp Ib–depleted platelets are not susceptible to the inhibitory action of heparin.
The large number of studies performed on the heparin effect on platelet function have provided conflicting results. Although many studies have suggested that heparin could enhance platelet aggregation in vitro\textsuperscript{21,22} and promote platelet activation in vivo\textsuperscript{23,24} some clinical observations indicate an antiplatelet effect of heparin. In fact, therapeutic heparin administration may cause hemorrhages apparently not dependent on the heparin anticoagulant effect,\textsuperscript{25} a prolongation of the bleeding time,\textsuperscript{26} and platelet defects.\textsuperscript{27} Furthermore, heparin is beneficial in clinical situations in which platelet activation and arterial thrombus formation are the main pathogenetic mechanisms.\textsuperscript{28} Altogether, these findings suggest that heparin could have an “antiplatelet” effect in vivo.

The study reported here provides a mechanism for the platelet functional inhibition by heparin. This mechanism may play a relevant role in vivo. In fact, the concentrations of unfractionated heparin achievable in vivo during a standard intravenous infusion therapy are in the same range as that used in this study, ie, 0.1 to 5 U/mL, equal to 0.05 to 2.5 μmol/L.\textsuperscript{29} Both HMW and LMW heparins showed this effect, and it seems to be directly related to the mean MW of molecules.

Heparin has a similar inhibitory effect on vWF-Gp Ib interaction, which may partially account for its antiplatelet effect.\textsuperscript{30} It is noteworthy that in this case also, the inhibitory effect is due to heparin interaction with a vWF HBS involved in Gp Ib ligation.

The effect of heparin on thrombin-induced platelet activation opens a potentially broad area for further investigation and therapeutic application. The demonstration that the magnitude of inhibition is related to the MW of heparin could open the way to new strategies for a discrete control of platelet response to thrombin stimulation in different clinical settings.

Acknowledgments

This study was supported in part by the Per il Cuore Foundation. The authors are indebted to Dr R.K. Andrews (Baker Medical Research Institute, Prahran, Australia) for kindly providing the mocarhagin used in this study. The authors are also grateful to Dr C. Rumi and to Dr S. Rutella (Istituto di Semeiotica Medica, Università Cattolica, Roma) for flow cytometry assays.

References

Thrombin-Induced Platelet Activation Is Inhibited by High- and Low-Molecular-Weight Heparin
E. De Candia, R. De Cristofaro and R. Landolfi

Circulation. 1999;99:3308-3314
doi: 10.1161/01.CIR.99.25.3308

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1999 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/99/25/3308

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/